Cephalosporins are beta-lactam antibiotics in which the four-membered beta-lactam ring is fused to a six-membered dihydrothiazine ring, producing the cephem scaffold. This structural difference from penicillins (which have a five-membered thiazolidine ring) confers greater intrinsic stability to many beta-lactamases and allows more diverse side-chain substitution, forming the basis for the generational classification.
Structure and Side Chains. The cephalosporin nucleus is 7-aminocephalosporanic acid (7-ACA). Side chains at the 7-position R1 (position-1 substituent, analogous to the 6-position in penicillins) determine antibacterial spectrum and beta-lactamase stability. Side chains at the 3-position (R2) influence pharmacokinetic (PK) properties including protein binding, half-life, and biliary versus renal elimination. The R1 aminothiazole side chain present in third- and fourth-generation cephalosporins confers enhanced gram-negative penetration and stability against many class A beta-lactamases. The cross-reactivity between penicillins and cephalosporins is determined primarily by R1 side chain similarity rather than by the shared beta-lactam ring or the ring fusion structure.1
Mechanism of Action. Cephalosporins act identically to penicillins: the beta-lactam carbonyl forms a covalent acyl-enzyme intermediate with the active-site serine of penicillin-binding protein (PBP) transpeptidases, irreversibly inhibiting peptidoglycan cross-linking. Different cephalosporins preferentially bind different PBP (penicillin-binding protein) subtypes: first-generation agents bind PBP1 (transpeptidase) and PBP3 (cell division transpeptidase) in gram-positive organisms; third-generation agents have high affinity for PBP3 in Enterobacteriaceae; cefepime (a fourth-generation cephalosporin) binds PBP2 (cell shape transpeptidase) with high affinity in Pseudomonas aeruginosa; ceftaroline (fifth-generation) uniquely binds PBP2a in methicillin-resistant Staphylococcus aureus (MRSA). The pharmacodynamic (PD) driver of cephalosporin efficacy is time-dependent killing, with the target pharmacodynamic index being fT>MIC (percentage of the dosing interval that free drug concentration exceeds the minimum inhibitory concentration), typically 40-70% for bactericidal effect depending on the agent and organism.2
Beta-Lactamase Stability. The progressive beta-lactamase stability across cephalosporin generations reflects structural modifications that provide steric protection of the beta-lactam ring. First-generation cephalosporins are hydrolyzed by staphylococcal penicillinase and by many gram-negative beta-lactamases. Second-generation agents have improved stability against some class A and class C enzymes. Third-generation agents are stable to TEM-1 (TEM: named for patient Temoniera), SHV-1 (sulhydryl-variable enzyme type 1), and AmpC (class C cephalosporinase) enzymes but are efficiently hydrolyzed by extended-spectrum beta-lactamases (ESBLs) such as CTX-M (cefotaxime-Munich enzyme) and by carbapenemases. Fourth-generation cephalosporins (cefepime) have a zwitterionic structure that penetrates the outer membrane rapidly and is more stable to AmpC hydrolysis but not to ESBL (extended-spectrum beta-lactamase) hydrolysis. Ceftazidime-avibactam and related novel combinations restore activity against ESBL and KPC (Klebsiella pneumoniae carbapenemase)-producing organisms by protecting the beta-lactam ring with a non-beta-lactam inhibitor.8
Ceftaroline is the first beta-lactam with clinically meaningful affinity for PBP2a, the low-affinity transpeptidase encoded by the mecA gene that confers methicillin resistance. This property makes ceftaroline the only approved beta-lactam with in vitro and clinical activity against MRSA. Its approved indications are acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). It does not have approval for MRSA bacteremia, though it has been used off-label in that setting, including as a synergistic partner with vancomycin or daptomycin for salvage therapy of persistent MRSA bacteremia.
The generational classification of cephalosporins reflects the progressive broadening of gram-negative spectrum accompanied by relative loss of gram-positive activity (with the exception of ceftaroline). Understanding the spectrum of each generation at the level of specific organisms, rather than as a vague continuum, is essential for rational empiric and definitive antibiotic selection.
First-Generation Cephalosporins. First-generation agents (cefazolin, cephalexin, cefadroxil) have excellent activity against methicillin-susceptible Staphylococcus aureus (MSSA) and streptococci, and limited gram-negative coverage restricted to community-acquired Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae (the classic non-SPACE organisms). They have no meaningful activity against Enterococcus species, MRSA (methicillin-resistant Staphylococcus aureus), Pseudomonas aeruginosa, or anaerobes. Cefazolin is the most widely used first-generation agent: it is the preferred agent for surgical prophylaxis across most surgical specialties (replacing older alternatives), is the drug of choice for MSSA infections in patients who cannot tolerate antistaphylococcal penicillins, and is preferred for MSSA skin and soft tissue infections when intravenous therapy is required. Cephalexin is the oral first-generation agent of choice for outpatient MSSA and streptococcal skin infections. Cefazolin has low cross-reactivity with penicillin due to its unique 3-position side chain not shared by any penicillin.3
Second-Generation Cephalosporins. Second-generation agents include two clinically distinct subgroups: the true cephalosporins (cefuroxime, cefaclor, cefprozil) and the cephamycins (cefoxitin, cefotetan). True second-generation cephalosporins extend gram-negative coverage beyond first-generation agents to include Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis, and some Enterobacteriaceae, while retaining good gram-positive activity. Cefuroxime is used orally for outpatient respiratory tract infections and intravenously for mild to moderate hospital infections. The cephamycins cefoxitin and cefotetan extend coverage to anaerobes through a unique 7-alpha-methoxy group that protects the beta-lactam ring from anaerobic beta-lactamases; they are used for intra-abdominal and gynecologic infections involving Bacteroides fragilis. Cephamycins are also stable to AmpC (class C cephalosporinase) but are susceptible to ESBL (extended-spectrum beta-lactamase) hydrolysis.4
Third-Generation Cephalosporins. Third-generation agents (ceftriaxone, cefotaxime, ceftazidime) have substantially expanded gram-negative spectrum including most Enterobacteriaceae, H. influenzae, and N. gonorrhoeae, at the cost of reduced antistaphylococcal potency compared to first-generation agents. Ceftriaxone is the most clinically important third-generation agent: it has a long half-life of approximately 8 hours allowing once-daily dosing, excellent CSF (cerebrospinal fluid) penetration making it the standard of care for bacterial meningitis caused by susceptible organisms, and biliary elimination (approximately 40%) that makes it an option in severe renal impairment without dose adjustment. Ceftriaxone is the drug of choice for community-acquired pneumonia (CAP) requiring hospitalization, spontaneous bacterial peritonitis (SBP), and most gram-negative bacteremias caused by susceptible organisms. Ceftazidime is the third-generation agent with antipseudomonal activity but reduced gram-positive coverage; it is used in combination (as ceftazidime-avibactam) for carbapenem-resistant organisms.8
Fourth-Generation Cephalosporins. Cefepime is the only widely available fourth-generation cephalosporin. Its zwitterionic structure (bearing both positive and negative charges) allows rapid penetration through gram-negative outer membrane porins and confers enhanced stability against chromosomal AmpC cephalosporinases (class C). Cefepime covers Pseudomonas aeruginosa, most Enterobacteriaceae including AmpC-producing organisms, and retains good gram-positive activity including streptococci and MSSA comparable to first-generation agents. It is a first-line empiric agent for febrile neutropenia and for nosocomial infections where Pseudomonas is a concern. Cefepime is susceptible to ESBL (extended-spectrum beta-lactamase) hydrolysis; isolates testing susceptible to cefepime with a borderline MIC (minimum inhibitory concentration) in ESBL producers may carry a risk of clinical failure (the "inoculum effect"), though cefepime MIC-directed therapy may be appropriate in some clinical situations based on current CLSI (Clinical and Laboratory Standards Institute) interpretive criteria.2
Fifth-Generation Cephalosporins. Ceftaroline fosamil is the prodrug of ceftaroline, the only FDA (US Food and Drug Administration)-approved beta-lactam with MRSA activity through penicillin-binding protein (PBP) 2a binding. Its spectrum includes MRSA, MSSA, streptococci, and most gram-negative Enterobacteriaceae, but it lacks antipseudomonal activity and anaerobic coverage. Ceftolozane-tazobactam, though not a fifth-generation cephalosporin by traditional classification, is a novel cephalosporin-inhibitor combination with enhanced antipseudomonal activity and stability against derepressed AmpC overproduction in Pseudomonas, used for multidrug-resistant Pseudomonas infections. It is not active against ESBL-producing Enterobacteriaceae or carbapenem-resistant organisms.6
| Generation | Key Agents | Gram-Positive | Gram-Negative | Key Clinical Use |
|---|---|---|---|---|
| 1st | Cefazolin, Cephalexin | Excellent (MSSA, strep) | E. coli, Proteus, Klebsiella (non-ESBL) | Surgical prophylaxis; MSSA infections; skin/soft tissue |
| 2nd | Cefuroxime; Cefoxitin (cephamycin) | Good | + H. influenzae, M. catarrhalis; cephamycins add anaerobes | Respiratory infections; intra-abdominal (cefoxitin) |
| 3rd | Ceftriaxone, Cefotaxime, Ceftazidime | Moderate (weaker than 1st) | Broad Enterobacteriaceae; ceftazidime adds Pseudomonas | Meningitis; CAP; SBP; gram-neg bacteremia |
| 4th | Cefepime | Good (comparable to 1st) | Pseudomonas; AmpC-stable; not ESBL | Febrile neutropenia; nosocomial infections |
| 5th | Ceftaroline | MRSA + MSSA + strep | Enterobacteriaceae (no Pseudomonas) | ABSSSI; CABP; MRSA (off-label bacteremia) |
Beta-lactamase inhibitors (BLIs) are compounds that inactivate beta-lactamase enzymes, restoring the activity of the paired beta-lactam against beta-lactamase-producing organisms. The first three classical inhibitors (clavulanic acid, sulbactam, tazobactam) are mechanism-based, irreversible serine active-site inhibitors effective against class A beta-lactamases but inactive against class B metallo-beta-lactamases and class C AmpC enzymes. The newer diazabicyclooctane (DBO) inhibitors (avibactam, relebactam, vaborbactam) extend coverage to class A, C, and some class D enzymes, enabling activity against carbapenem-resistant Enterobacteriaceae (CRE).
Classical Inhibitors: Clavulanic Acid, Sulbactam, and Tazobactam. Clavulanic acid, sulbactam, and tazobactam are suicide inhibitors that form a stable acyl-enzyme intermediate with the active-site serine of class A beta-lactamases, irreversibly inactivating them. Clavulanic acid is the most potent inhibitor of TEM-1 (TEM penicillinase) and SHV-1 (sulhydryl-variable penicillinase) penicillinases and is combined with amoxicillin (amoxicillin-clavulanate) for oral therapy of respiratory and skin infections, and with ticarcillin (ticarcillin-clavulanate) for parenteral therapy. Tazobactam is a more potent inhibitor than clavulanic acid and is combined with piperacillin (piperacillin-tazobactam, pip-tazo) to restore activity against beta-lactamase-producing gram-negative organisms. Sulbactam has both inhibitory and limited intrinsic antibacterial activity, particularly against Acinetobacter baumannii, where it acts directly on PBP1 (transpeptidase) and PBP3 (cell division transpeptidase); sulbactam-durlobactam (combined with a novel DBO inhibitor) is now approved specifically for Acinetobacter infections. The classical inhibitors have no activity against AmpC, metallo-beta-lactamases, or ESBL (extended-spectrum beta-lactamase) CTX-M (cefotaxime-Munich enzyme) enzymes at clinically achievable concentrations in the context of bacteremia (the inoculum effect).7
Novel Inhibitors: Avibactam, Relebactam, and Vaborbactam. Avibactam is a diazabicyclooctane (DBO) inhibitor that covalently but reversibly inhibits class A (including ESBL and KPC), class C (AmpC), and some class D (OXA-48) serine beta-lactamases. Unlike classical inhibitors, avibactam is not a suicide inhibitor: the acyl-enzyme intermediate can deacylate and the intact avibactam molecule is regenerated, allowing a single avibactam molecule to inactivate multiple enzyme molecules. Avibactam is combined with ceftazidime (ceftazidime-avibactam) and is approved for complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and infections caused by aerobic gram-negative organisms with limited treatment options including KPC-producing Klebsiella pneumoniae. Relebactam, another DBO inhibitor combined with imipenem-cilastatin (imipenem-relebactam), restores carbapenem activity against KPC-producing organisms and derepressed AmpC producers, and is approved for cUTI and HAP. Vaborbactam is a cyclic boronic acid inhibitor combined with meropenem (meropenem-vaborbactam), also active against KPC but not metallo-beta-lactamases or OXA-48.8
Amoxicillin-Clavulanate: ADME (Absorption, Distribution, Metabolism, Excretion) and Clinical Considerations. Amoxicillin-clavulanate (co-amoxiclav) is the most widely prescribed oral antibiotic combination globally. The standard adult formulation (875 mg amoxicillin/125 mg clavulanate twice daily) delivers sufficient clavulanate to inhibit beta-lactamase-producing H. influenzae, Moraxella catarrhalis, and beta-lactamase-producing E. coli and Klebsiella. Clavulanate is associated with gastrointestinal adverse effects (nausea, diarrhea) that limit tolerability; the extended-release formulation (2000 mg/125 mg) reduces the clavulanate-to-amoxicillin ratio to improve tolerability while increasing amoxicillin exposure for pharmacokinetic optimization. Amoxicillin-clavulanate is associated with a higher incidence of Clostridioides difficile (formerly Clostridium difficile) infection compared to amoxicillin alone. Cholestatic hepatitis (elevated alkaline phosphatase (ALP) and direct bilirubin) is a recognized but uncommon adverse effect of clavulanate, occurring more frequently in elderly patients and with prolonged use.9
Piperacillin-Tazobactam: Spectrum, Dosing, and the ESBL Limitation. Piperacillin-tazobactam covers Pseudomonas aeruginosa, most Enterobacteriaceae, anaerobes, streptococci, and Enterococcus faecalis, making it one of the broadest-spectrum beta-lactam combinations available. Standard dosing is 3.375 g (piperacillin 3 g/tazobactam 0.375 g) every 6 hours or 4.5 g every 6 or 8 hours; extended infusion over 4 hours is used in some institutions to optimize fT>MIC (time above minimum inhibitory concentration) against organisms with elevated MICs. The MERINO (multicenter randomized trial of piperacillin-tazobactam versus meropenem) (multicenter randomized trial of piperacillin-tazobactam versus meropenem) established that pip-tazo should not be used as definitive therapy for ESBL-producing E. coli or Klebsiella bacteremia regardless of in vitro susceptibility, due to the inoculum effect overwhelming tazobactam inhibition at the high bacterial burdens encountered in bacteremia. Pip-tazo remains appropriate for empiric therapy of hospital-acquired infections while awaiting culture results, and as definitive therapy for infections caused by non-ESBL beta-lactamase producers confirmed susceptible by validated testing.10
Resistance to ceftazidime-avibactam in KPC-producing organisms can emerge rapidly during therapy through mutations in the blaKPC gene (the gene encoding KPC beta-lactamase) that reduce avibactam binding affinity (D179Y, T243M mutations are most common), or through upregulation of efflux pumps and porin loss. Emerging resistance has been documented clinically, particularly during prolonged monotherapy. Current practice for serious KPC infections often employs combination regimens or sequential therapy. Ceftazidime-avibactam is not active against metallo-beta-lactamases (NDM, VIM, IMP); meropenem-vaborbactam and imipenem-relebactam share this limitation. For NDM-producing organisms, cefiderocol (a novel siderophore cephalosporin) or aztreonam-avibactam may be options.
The clinical management of cephalosporin use in penicillin-allergic patients has been substantially revised by immunologic and pharmacoepidemiologic evidence over the past two decades. The commonly cited 10% cross-reactivity rate between penicillins and cephalosporins is no longer supported and has been replaced by a side-chain-based assessment framework. Alongside allergy considerations, the pharmacokinetic properties of cephalosporins determine clinical niche: biliary versus renal elimination, CSF (cerebrospinal fluid) penetration, and protein binding all influence agent selection for specific infection sites. CNS (central nervous system) penetration is a distinct consideration for meningitis.
Cross-Reactivity: The R1 (position-1 substituent) Side Chain Rule. Current evidence from skin testing studies and graded challenge trials consistently demonstrates that cephalosporin-penicillin cross-reactivity is mediated by shared R1 side chains rather than by the shared beta-lactam ring or ring fusion structures. The true incidence of cross-reactivity between penicillins and structurally dissimilar cephalosporins is approximately 1-2%, not the historically cited 10%. Cephalosporins that share R1 side chains with amoxicillin (cefadroxil, cefprozil, cefatrizine) have a meaningfully higher cross-reactivity risk in patients with documented amoxicillin allergy. Cefazolin is the cephalosporin with the lowest penicillin cross-reactivity risk because its R1 side chain (a tetrazolylthiomethyl group) is structurally unrelated to any penicillin side chain; it may be safely used for surgical prophylaxis in most penicillin-allergic patients after appropriate allergy evaluation, with the exception of those who have experienced IgE (immunoglobulin E)-mediated reactions to cefazolin itself.11
Cephalosporin Pharmacokinetics and CNS Penetration. Most cephalosporins are eliminated predominantly renally via glomerular filtration and active tubular secretion, requiring dose adjustment in renal impairment. Ceftriaxone is the major exception: it is approximately 40% eliminated by biliary secretion (as unchanged drug excreted in bile), and the remainder renally. This dual elimination means ceftriaxone does not require dose adjustment in renal impairment and is preferred for gram-negative bacteremia in patients with acute kidney injury. However, ceftriaxone should be used with caution in neonates (risk of bilirubin displacement) and avoided in combination with calcium-containing intravenous solutions due to precipitation risk. CSF penetration is clinically adequate for ceftriaxone, cefotaxime, and cefepime when meningeal inflammation is present, supporting their use for bacterial meningitis caused by susceptible organisms. Ceftazidime also achieves adequate CSF concentrations and is used for gram-negative meningitis including Pseudomonas meningitis in appropriate clinical settings.5
Cefepime Neurotoxicity. Cefepime accumulation in patients with renal impairment is associated with a dose-dependent encephalopathy that is underrecognized in clinical practice. Cefepime neurotoxicity manifests as non-convulsive status epilepticus (NCSE), myoclonus, confusion, and impaired consciousness; the electroencephalogram (EEG) typically shows generalized epileptiform discharges or triphasic waves. The mechanism involves competitive inhibition of GABA-A (gamma-aminobutyric acid type A) receptors by cefepime in the CNS (central nervous system), a property shared to a lesser extent by other cephalosporins. Neurotoxicity has been reported even with seemingly appropriate dose adjustments based on estimated GFR (glomerular filtration rate); augmented renal clearance in acutely ill patients may require higher doses, while patients with impaired clearance are at heightened risk. Dose adjustment nomograms for cefepime in renal impairment are required, and cefepime should be discontinued and an alternative considered if unexplained encephalopathy develops during therapy.2
Clinical Selection Framework. The selection of a cephalosporin for a specific clinical indication integrates spectrum, pharmacokinetics, institutional resistance patterns, allergy status, and cost. For empiric community-acquired infections, ceftriaxone covers the expected pathogens in most outpatient and hospitalized settings. For nosocomial infections where Pseudomonas is a concern, cefepime or piperacillin-tazobactam are appropriate empiric choices; ceftazidime is reserved for specific indications or multidrug-resistant Pseudomonas in combination with avibactam. For infections in geographic areas or institutions with high ESBL (extended-spectrum beta-lactamase) prevalence, empiric carbapenem therapy is generally preferred for sepsis or bacteremia while awaiting culture results; broader use of ceftazidime-avibactam or other novel combinations should be guided by microbiology and infectious disease consultation to preserve these agents. For MRSA (methicillin-resistant Staphylococcus aureus)-suspected skin infections, ceftaroline provides a beta-lactam option, though the clinical benefit over vancomycin or daptomycin for MRSA bacteremia remains under investigation.6
Cefazolin for surgical prophylaxis in penicillin-allergic patients: safe in most patients after allergy risk stratification; lowest cephalosporin cross-reactivity risk. Ceftriaxone for meningitis: 2 g IV every 12 hours; add ampicillin if Listeria is possible (age over 50, immunocompromised). Cefepime neurotoxicity: check renal function and adjust dose; evaluate unexplained encephalopathy in ICU patients on cefepime with EEG. Ceftazidime-avibactam for KPC-CRE: do not use for metallo-beta-lactamase producers; confirm KPC vs NDM with genotypic testing. Piperacillin-tazobactam for ESBL bacteremia: avoid as definitive therapy regardless of in vitro susceptibility (MERINO trial evidence).
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet. 2019;393(10167):183-198.
doi:10.1016/S0140-6736(18)32218-9Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
doi:10.1093/cid/ciw353Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.
doi:10.2146/ajhp120568Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164.
doi:10.1086/649554van de Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. Nat Rev Dis Primers. 2016;2:16074.
doi:10.1038/nrdp.2016.74Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31-51.
doi:10.1007/s40265-013-0168-2Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160-201.
doi:10.1128/CMR.00037-09Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2):e01964-16.
doi:10.1128/AAC.01964-16Tholakanahalli VN, Pottage JC, Stamos JK. Amoxicillin-clavulanate-induced cholestatic hepatitis. West J Med. 1996;165(3):202-203.
doi:10.1136/ewjm.165.3.202-aHarris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984-994.
doi:10.1001/jama.2018.12163Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation. J Allergy Clin Immunol Pract. 2017;5(3):616-625.e7.
doi:10.1016/j.jaip.2017.02.019